检索结果-南通市图书馆

Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients

World Journal of Clinical Cases 2022年第14期10卷 4327-4333页

作者： hala najeeb Farah Yasmin Salim Surani Department of Internal Medicine Dow University of Health SciencesKarachi 74200Pakistan Department of Medicine Texas A&M UniversityCollege StationTX 77843United States Department of Anesthesiology Mayo ClinicRochesterMN 55905United States

The increasing incidence of inflammatory bowel disease(IBD)globally has redirected the healthcare system's focus towards safe and affordable pharmacological *** inception of anti-tumor necrosis factor-α(TNF-α)had resulted in a trend shift from surgical ***,as the patents of approved anti-TNF-αdrugs expire,biological copies of the many approved products are in the *** most commonly used biosimilar for IBD has been infliximab,followed by Adalimumab biosimilars which have been approved in major countries across the *** biosimilars are approved on the basis of similarity of their reference product,the lack of real-world evidence of its safety in ulcerative colitis and Crohn’s disease patients has contributed to physicians’***,biosimilars are expected to reduce treatment costs and provide economic benefits.

关键词： Inflammatory bowel disease Biosimilars Anti-tumor necrosis factor Infliximab Adalimumab Ulcerative colitis Chrons disease

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Apheresis:A cell-based therapeutic tool for the inflammatory bowel disease

引用

World Journal of Clinical Cases 2022年第21期10卷 7195-7208页

作者： Farah Yasmin hala najeeb Unaiza Naeem Abdul Moeed Thoyaja Koritala Salim Surani Department of Medicine DOW University of Health SciencesKarachi 74200Pakistan Department of Medicine Mayo ClinicRochesterMN 55902United States Department of Medicine Texas A&M UniversityCollege StationTexas 77843United States Department of Anaesthesiology Mayo ClinicRochesterMN 55902United States

Inflammatory Bowel Disease(IBD)is a hallmark of leukocyte infiltration,followed by the release of cytokines and *** progression to Ulcerative Colitis(UC)or Crohn’s Disease(CD)remained largely *** genetic and environmental factors disrupt enteral bacteria in the gut,which hampers the intestinal repairing capability of damaged *** practiced pharmacological therapies include 5-aminosalicylic acid with corticosteroids and tumor necrosis factor(TNF)-α.New interventions such as CDP571 and TNF-blocking RDP58 report the loss of patient *** review discusses the non-pharmacologic selective granulocyte–monocyte-apheresis(GMA)and leukocytapheresis(LCAP)that have been proposed as treatment modalities that reduce ***,an extracorporeal vein-to-vein technique,presents a strong safety profile case for its use as a viable therapeutic option compared to GMA's conventional medication safety *** reported minimal to no side effects in the pediatric population and pregnant *** studies report the efficacious nature of GMA in UC patients,whereas data on CD patients is *** benefits outweigh the risks and are emerging as a favored nonpharmacological treatment *** the contrary,LCAP uses a general extracorporeal treatment that entraps leukocytes and suppresses cytokine *** has been deemed more efficacious than conventional drug treatments,the former causing better disease remission,and *** with UC/CD secondary to complications have responded well to the *** effects of the procedure have remained mild to moderate,and there is little evidence of any severe adverse event occurring in most age *** decreases the dependence on steroids and immunosuppressive therapies for *** review will discuss the role of GMA and LCAP.

关键词： Inflammatory bowel disease Apheresis Granulocyte-monocyte-apheresis Leukocytapheresis TNF-α Ulcerative colitis Crohn’s disease

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Novel drug delivery systems for inflammatory bowel disease

引用

World Journal of Gastroenterology 2022年第18期28卷 1922-1933页

作者： Farah Yasmin hala najeeb Shehryar Shaikh Muhammad Hasanain Unaiza Naeem Abdul Moeed Thoyaja Koritala Syedadeel Hasan Salim Surani Department of Medicine Dow University of Health ScienceKarachi 74200Pakistan Department of Medicine Dow OJha University HospitalKarachi 74200Pakistan Department of Medicine Mayo Clinic Health SystemMankatoMN 56001United States Department of Medicine University of LouisvilleLouisvilleKY 40292United States Department of Medicine Texas A&M UniversityCollege StationTX 77843United States Department of Anesthesiology Mayo ClinicRochesterMN 55901United States

Inflammatory bowel disease(IBD)is a chronic illness characterized by relapsing inflammation of the *** disorder is stratified according to the severity and is marked by its two main phenotypical representations:Ulcerative colitis and Crohn’s *** of the disease is ambiguous and is expected to have interactivity between genetic disposition,environmental factors such as bacterial agents,and dysregulated immune *** for IBD aims to reduce symptom extent and severity and halt disease *** mainstay drugs have been 5-aminosalicylates(5-ASAs),corticosteroids,and immunosuppressive ***,oral and rectal routes are the conventional methods of drug delivery,and among all,oral administration is most widely ***,problems of systematic drug reactions and low specificity in delivering drugs to the inflamed sites have emerged with these regular routes of *** drug delivery systems have been introduced to overcome several therapeutic obstacles and for localized drug delivery to target ***-coated microneedle pills,various nano-drug delivery techniques,prodrug systems,lipid-based vesicular systems,hybrid drug delivery systems,and biologic drug delivery systems constitute some of these novel *** are painless,they dislodge their content at the affected site,and their release can be *** bacteria such as genetically engineered Lactococcus Lactis and eukaryotic cells,including GM immune cells and red blood cells as nanoparticle carriers,can be plausible delivery methods when evaluating biologic ***-particle drug delivery systems consisting of various techniques are also employed as nanoparticles can penetrate through inflamed regions and adhere to the thick mucus of the diseased *** systems such as 5-ASAs formulations or their derivatives are effective in reducing colonic *** can be modified with both hydrophilic and lipophilic p

关键词： Inflammation Inflammatory bowel diseases Colitis Ulcerative Crohn’s disease Drug delivery systems Drug carrier

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：